Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustradiationcellchemotherapyrecurrent
  Phrases that lowered it: ritonavirweekshepaticpartnertrial
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.3% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 13.1% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 60 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports marked serious: 90.5% (raises risk) · Drug's FDA history
• Keywords listed: 10 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme NCT00915694 · started 2009 · scored riskier than 60% of active trials terminated
• A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma NCT01020292 · started 2009 · scored riskier than 76% of active trials completed
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) NCT03355794 · started 2017 · scored riskier than 65% of active trials completed
• Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma NCT01026493 · started 2010 · scored riskier than 71% of active trials completed
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas NCT01478321 · started 2011 · scored riskier than 79% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.